ResearcherUniversity of MichiganActive in the last 2 years
Thomas Enzler
Matched on ORCID iD 0000-0002-8775-1493; OpenAlex author ID A5088300643. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 20
2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper
Papers 7
- Case Report: An exceptional response to a novel immunotherapy-based combination treatment for resected pancreatic ductal adenocarcinoma with recurrence to the … Co-author DOI 10.3389/fonc.2026.1649850↗
- Pancreatic cancer precursor lesions - Can immunotherapy prevent progression into pancreatic ductal adenocarcinoma? Co-author DOI 10.1016/j.canlet.2025.217662↗
- A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreat… Co-author DOI 10.1016/j.ejca.2024.113950↗
- A Comparison of Spatial and Phenotypic Immune Profiles of Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions. Co-author DOI 10.3390/ijms25052953↗
- Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma. First author DOI 10.1080/2162402x.2022.2066767↗
- Emerging antibody therapies for pancreatic adenocarcinoma: a review of recent phase 2 trials. Co-author DOI 10.1080/14728214.2021.1905795↗
- Clinical Trials in Pancreatic Cancer: A Long Slog. Co-author DOI 10.1634/theoncologist.2017-0453↗
Closest collaborators
The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Timothy L. Frankel · 2 shared papers, 2024–2025 · strength 0.76
- Paper Pancreatic cancer precursor lesions - Can immunotherapy prevent progression into pancreatic ductal adenocarcinoma? DOI 10.1016/j.canlet.2025.217662↗
- Paper A Comparison of Spatial and Phenotypic Immune Profiles of Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions. DOI 10.3390/ijms25052953↗
- Vaibhav Sahai · 3 shared papers, 2021–2024 · strength 0.59
- Paper A Comparison of Spatial and Phenotypic Immune Profiles of Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions. DOI 10.3390/ijms25052953↗
- Paper Emerging antibody therapies for pancreatic adenocarcinoma: a review of recent phase 2 trials. DOI 10.1080/14728214.2021.1905795↗
- Paper A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line trea… DOI 10.1016/j.ejca.2024.113950↗
- Laura Webb Lamps · 1 shared paper, 2026 · strength 0.43
- Susan Elaine Bates · 2 shared papers, 2017–2022 · strength 0.26
- Brian D. Griffith · 1 shared paper, 2024 · strength 0.23
- Hari Nathan · 1 shared paper, 2024 · strength 0.23
- Jiaqi Shi · 1 shared paper, 2024 · strength 0.23
- Jasmeet Kaur · 1 shared paper, 2021 · strength 0.19
- Taichi Kawabe · 1 shared paper, 2024 · strength 0.17
- Donald Richards · 1 shared paper, 2024 · strength 0.17
- Mark M. Zalupski · 1 shared paper, 2024 · strength 0.17
- Wells A. Messersmith · 1 shared paper, 2024 · strength 0.17
- Yvonne M. Saenger · 1 shared paper, 2022 · strength 0.11
- Raúl Rabadán · 1 shared paper, 2022 · strength 0.11
- David Paul Horowitz · 1 shared paper, 2022 · strength 0.11
- Robyn D. Gartrell · 1 shared paper, 2022 · strength 0.11
- Michael D. Kluger · 1 shared paper, 2022 · strength 0.11
- Beth Schrope · 1 shared paper, 2022 · strength 0.11
- John A. Chabot · 1 shared paper, 2022 · strength 0.11
- Gulam Abbas Manji · 1 shared paper, 2022 · strength 0.11
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.